US FDA warns Shionogi over antibiotic promotion
WASHINGTON, Nov 25 (Reuters) - U.S. health regulators have warned Shionogi & Co Ltd's (4507.T) U.S. unit over misleading promotion of its antibiotic Cedax that omits the drug's risks and makes exaggerated claims, according to a letter released on Tuesday.
"These violations are concerning from a public health perspective because they suggest that the product is both safer and effective in a broader range of conditions than has been demonstrated by substantial evidence or substantial clinical experience," Thomas Abrams, head of the FDA's marketing division wrote in a letter to the company.
The letter, dated Nov. 14, was released on the FDA's website here. (Reporting by Susan Heavey, editing by Gerald E. McCormick)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
